The drug offers improved seizure control with minimal safety risks for patients with epilepsy
Alkem Laboratories has launched Brivasure, an affordable anti-epileptic drug for the treatment of epilepsy in India.
Brivasure, Alkem’s anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg Rs 79.50/strip, Brivasure 50mg 148.50/strip, Brivasure 75mg 230/strip, Brivasure 100mg 295/strip, post-patent expiry of innovator product, of Brivaracetam as on February 21, 2021. The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial-onset seizure with or without secondary generalisation. The drug has exhibited a faster onset of action, efficacy with a favourable safety profile.
Yogesh Kaushal, President, Chronic Business, Alkem said, “With over 500 scientists working in 6 global R&D centres, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’. With the launch of Brivasure, we aim to make the treatment of Epilepsy easily accessible to the patients at affordable pricing. We believe that healthcare is not just about curing people but enriching their lives. The introduction of Brivasure is a testimony to our commitment to improving the quality of life and treatment compliance of epilepsy patients in India.”
Dr Akhilesh Sharma, President and CMO, Alkemadded, “The magnitude of epilepsy treatment gap in India is very high and ranges from 22 per cent in urban to 90 per cent in rural India. Making effective and high-quality anti-epileptic drugs more affordable and accessible to these patients is the need of the hour. Alkem has always been on the forefront, trusted by healthcare professionals as well as patients for over four decades now. With the introduction of brivaracetam by Alkem, we are optimistic about making steady progress and revolutionizing Epilepsy treatment in India as well as globally. Levetiracetam has been considered a broad-spectrum antiepileptic drug in India but after clinical usage, for over a decade we have learnt that it has got its disadvantages and is associated with certain behavioural side effects. Brivaracetam seems to be filling up this gap with its promising efficacy which was observed even in those patients who had previously discontinued Levetiracetam due to side effects, benign side effects and simpler dosing regimen making it more convenient and cost-effective proposition for the patients.”
